Over the last five years, we've done 19 systemic reviews—now with this one, it's 20—to give you a sense.
We had a pretty static five-year program where we were looking at the top 17 departments in terms of value and volume and looking at three static lines of inquiry to be able to assess...to almost create baseline data. Now that we've created that baseline data, it's a really important launch pad for us to know where to look next.
ArriveCAN was a bit of an anomaly. It was brought to us by the committee, but ultimately we were able to find reasonable grounds to launch. As a result, we were able to do this review. There's another review also coming as a result of this committee's action on McKinsey.